In contrast, compounds that can inhibit both ligand-dependent and ligand-independent functions of GR, such as ORIC-101, suppress the expression of FOXA1/GR targets below baseline levels, and inhibit proliferation and tumor growth in a dose-dependent manner. The gene discussed is NR3C1; the disease is neoplasm.